These findings not only advance our understanding of HCC immune evasion but also lay the groundwork for developing ATP6AP1-targeted therapies, offering a transformative strategy to overcome current limitations in HCC immunotherapy. Here, ATP6AP1 is linked to hepatocellular carcinoma.